The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
400 jobs Number of planned job losses
Announcement Date
4 December 2012
Employment effect (start)
4 December 2012
Foreseen end date
Description
As announced on December 4, 2012 pharmaceutical company AstraZeneca will cut 400 jobs in Germany. This is due to decreasing sales. Job redundancies include back office workers and sales representatives.
Forced redundancies are to be avoided and job cuts shall be realised by early retirement and voluntary separation.
AstraZeneca suffers from expiring patent protections and therefore reduced prices induced by competition. In total, the company employs 1,025 people in Germany.
Sources
4 December 2012: AstraZeneca
5 December 2012: Handelsblatt
Citation
Eurofound (2012), AstraZeneca, Internal restructuring in Germany, factsheet number 74636, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/74636.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
